ARK Investment Management Portfolio holdings
ARK Investment Management LLC, founded in 2014 by Cathie Wood and headquartered in St. Petersburg, Florida, is an investment firm managing over $15 billion in assets as of late 2024, renowned for its focus on disruptive innovation across thematic equity ETFs. With a mission to invest in technologies shaping the future, ARK targets five key areas—artificial intelligence, genomics, autonomous technology, energy storage, and blockchain—offering funds like the ARK Innovation ETF (ARKK) to retail and institutional investors seeking high-growth opportunities. Wood, a former AllianceBernstein economist, leads a team of about 50, emphasizing active management, deep research, and a long-term horizon, often holding volatile, speculative stocks like Tesla and Coinbase, which fueled massive gains in 2020 but faced challenges in 2022’s bear market. Known for its transparent, educational approach—including daily portfolio disclosures and bold predictions like Bitcoin reaching $1 million—ARK has carved a niche as a forward-thinking, risk-embracing player in the investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ionis Pharmaceuticals
IONS
|
+$5.43M |
| 2 |
Qualcomm
QCOM
|
+$4.78M |
| 3 |
Editas Medicine
EDIT
|
+$4.76M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$4.47M |
| 5 |
XLNX
Xilinx Inc
XLNX
|
+$4.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Illumina
ILMN
|
+$5.87M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$5.43M |
| 3 |
Netflix
NFLX
|
+$4.48M |
| 4 |
3D Systems Corp
DDD
|
+$3.58M |
| 5 |
NVIDIA
NVDA
|
+$3.51M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.09% |
| 2 | Healthcare | 20.07% |
| 3 | Communication Services | 14.97% |
| 4 | Industrials | 13.28% |
| 5 | Consumer Discretionary | 11.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
UCTT
76
Ultra Clean Holdings
UCTT
$3.79B
| $312K | 0.09% |
18,514
-15,223
| -45% | -$202K |
|
|
MZOR
77
DELISTED
Mazor Robotics Ltd.
MZOR
| $311K | 0.09% |
10,448
+2,088
| +25% | +$49.2K |
|
78
Howmet Aerospace
HWM
$115B
| $282K | 0.08% |
13,959
+12,295
| +739% | +$242K |
|
79
Regeneron Pharmaceuticals
REGN
$78.2B
| $267K | 0.08% |
690
+68
| +11% | +$25.2K |
|
80
Aptiv
APTV
$10.1B
| $258K | 0.07% |
3,202
-1,333
| -29% | -$100K |
|
81
Flex
FLEX
$46.8B
| $258K | 0.07% |
20,387
+4,077
| +25% | +$48.8K |
|
82
Inovio Pharmaceuticals
INO
$68.5M
| $243K | 0.07% |
3,064
+462
| +18% | +$36.8K |
|
83
Allient
ALNT
$1.61B
| $236K | 0.07% |
17,581
+8,131
| +86% | +$120K |
|
84
United Parcel Service
UPS
$90.8B
| $214K | 0.06% |
1,996
-349
| -15% | -$38.1K |
|
85
Ametek
AME
$55.9B
| $210K | 0.06% |
3,891
+619
| +19% | +$32.6K |
|
86
Box
BOX
$4.4B
| $197K | 0.06% |
12,080
+245
| +2% | +$4.14K |
|
87
Incyte
INCY
$24.4B
| $193K | 0.06% |
1,442
-830
| -37% | -$106K |
|
|
FARO
88
DELISTED
Faro Technologies
FARO
| $190K | 0.05% |
5,301
+911
| +21% | +$33.2K |
|
|
SYRS
89
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $131K | 0.04% |
825
+478
| +138% | +$58.3K |
|
|
FPRX
90
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $128K | 0.04% |
3,551
+351
| +11% | +$15.5K |
|
91
Adobe
ADBE
$102B
| $115K | 0.03% |
887
+118
| +15% | +$13.8K |
|
|
CELG
92
DELISTED
Celgene Corp
CELG
| $111K | 0.03% |
895
+88
| +11% | +$10.5K |
|
|
NNDM
93
Nano Dimension
NNDM
$333M
| $89K | 0.03% |
1,333
+266
| +25% | +$16.8K |
|
94
NextTrip
NTRP
$25.5M
| $55K | 0.02% |
+89
| New | +$61.1K |
|
|
CLLS
95
Cellectis
CLLS
$277M
| $54K | 0.02% |
+2,254
| New | +$47.4K |
|
|
JNCE
96
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $40K | 0.01% |
+1,811
| New | +$38.4K |
|
97
Evogene
EVGN
$7.87M
| $39K | 0.01% |
738
+73
| +11% | +$3.8K |
|
98
Apple
AAPL
$4.52T
| $34K | 0.01% |
+956
| New | +$31.5K |
|
99
ATI
ATI
$26.4B
| $33K | 0.01% |
1,835
+619
| +51% | +$11.6K |
|
100
Eastman Chemical
EMN
$8.23B
| $33K | 0.01% |
413
+91
| +28% | +$7.16K |
|
Similar funds
ARK Investment Management's Q1 2017 Portfolio in Review
As of Q1 2017, ARK Investment Management held 109 positions worth $347M, up 26% from $275M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
ARK Investment Management deployed $23.1M of net new capital in Q1 2017, opening 7 new positions and adding to 73 existing holdings. Its largest new stake was Editas Medicine: 229,922 shares worth $5.13M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 27% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was Illumina, an estimated $5.87M trimmed.
- ARK Investment Management's largest Q1 2017 buy was Editas Medicine: 229,922 shares worth $5.13M.
- ARK Investment Management added most to Ionis Pharmaceuticals in Q1 2017, an estimated $5.43M increase.
- ARK Investment Management's biggest Q1 2017 reduction was Illumina, cutting an estimated $5.87M.
- ARK Investment Management fully exited Mentor Graphics Corp in Q1 2017, selling an estimated $512K.
- ARK Investment Management's ten largest holdings make up 44% of its $347M portfolio in Q1 2017.
- ARK Investment Management opened 7 new positions and closed 5 in Q1 2017.
- ARK Investment Management's portfolio value rose 26% quarter-over-quarter to $347M.
Based on ARK Investment Management's 13F filing for Q1 2017, filed 15 May 2017.